scholarly journals Bioinformatics Analysis of Global Proteomic and Phosphoproteomic Data Sets Revealed Activation of NEK2 and AURKA in Cancers

Biomolecules ◽  
2020 ◽  
Vol 10 (2) ◽  
pp. 237 ◽  
Author(s):  
Barnali Deb ◽  
Pratyay Sengupta ◽  
Janani Sambath ◽  
Prashant Kumar
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Colon Cancer ◽  
Human Tumor ◽  
Aurora Kinase ◽  
Data Sets ◽  
Cell Renal Cell Carcinoma ◽  
Cancer Management ◽  
Cancer Types ◽  
Cancer Côlon

Tumor heterogeneity attributes substantial challenges in determining the treatment regimen. Along with the conventional treatment, such as chemotherapy and radiotherapy, targeted therapy has greater impact in cancer management. Owing to the recent advancements in proteomics, we aimed to mine and re-interrogate the Clinical Proteomic Tumor Analysis Consortium (CPTAC) data sets which contain deep scale, mass spectrometry (MS)-based proteomic and phosphoproteomic data sets conducted on human tumor samples. Quantitative proteomic and phosphoproteomic data sets of tumor samples were explored and downloaded from the CPTAC database for six different cancers types (breast cancer, clear cell renal cell carcinoma (CCRCC), colon cancer, lung adenocarcinoma (LUAD), ovarian cancer, and uterine corpus endometrial carcinoma (UCEC)). We identified 880 phosphopeptide signatures for differentially regulated phosphorylation sites across five cancer types (breast cancer, colon cancer, LUAD, ovarian cancer, and UCEC). We identified the cell cycle to be aberrantly activated across these cancers. The correlation of proteomic and phosphoproteomic data sets identified changes in the phosphorylation of 12 kinases with unchanged expression levels. We further investigated phosphopeptide signature across five cancer types which led to the prediction of aurora kinase A (AURKA) and kinases-serine/threonine-protein kinase Nek2 (NEK2) as the most activated kinases targets. The drug designed for these kinases could be repurposed for treatment across cancer types.

Oncology Questions and Answers

2013 ◽  
pp. 79-82
Author(s):  
Robert D. Ficalora
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Lung Cancer ◽  
Ovarian Cancer ◽  
Colon Cancer ◽  
Multiple Choice ◽  
Cancer Breast ◽  
Questions And Answers ◽  
Board Review ◽  
Cancer Côlon

Chapter 8 presents multiple-choice, board review questions on oncology including lung cancer, colon cancer, ovarian cancer, breast cancer, and prostate cancer. Full explanations are provided with the correct answers.

Thromboembolic events in hospitalized cancer patients: Impact on stay duration and cost for four major cancer localizations.

2015 ◽  
Vol 33 (29_suppl) ◽  
pp. 186-186
Author(s):  
Florian Scotte ◽  
Alexandre Vainchtock ◽  
Nicolas Martelli ◽  
Isabelle Borget
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Lung Cancer ◽  
Colon Cancer ◽  
Hospital Stay ◽  
Cancer Patients ◽  
Thromboembolic Events ◽  
Cancer Management ◽  
Venous Thromboembolic Events ◽  
The Impact

186 Background: Cancer patients represent an at-risk population for Venous Thromboembolic Events (VTE). Our study aimed to evaluate the impact of VTE on the length and cost of hospital stay in French patients hospitalized for breast cancer (BC), colon cancer (CC), lung cancer (LC) or prostate cancer (PC). Methods: The French national hospital database (PMSI) and the disease-specific ICD-10 codes were used to identify BC, CC, LC or PC patients diagnosed in 2010 who were hospitalized with a VTE during the following two years. We selected stays during which a VTE occurred but was not the main reason of hospitalization (cancer was classified as primary/related diagnosis and VTE as significant associated diagnosis). Those stays were matched and compared to similar stays (same cancer and same reason for hospitalization) without VTE. Costs were calculated using the French official tariffs, from the perspective of the third-party payer. Results: We identified 214 stays for breast cancer during which a VTE occurred and was classified as significant associated diagnosis, 843 stays for colon cancer, 1301 for lung cancer, and 126 for prostate cancer. The comparison between those stays and similar stays without VTE showed significant increase of hospital stay duration in patients experiencing VTE. Median duration rose from 4 to 7 days in BC patients, from 8 to 16 days in CC, from 2 to 9 days in LC and from 6 to 10 days in PC. Consequently, the median expenditure per stay increased by 37% in BC patients with VTE (up to € 5,518), by 61% in CC (up to € 9,878), by 202% in LC (up to € 7,308) and by 22% in PC (up to € 6,200). Conclusions: When occurring during hospitalization, VTE made cancer management much heavier: patients faced prolonged hospital stays whereas healthcare system faced significant additional cost. Better prevention and follow-up measures could reduce this burden, and benefit both patients and hospitals. [Table: see text]

Synthesis and Anticancer Potentials of Quinoline Analogues: A Review of Literature

2020 ◽  
Vol 17 ◽  
Author(s):  
Ajay Kumar ◽  
Salahuddin ◽  
Avijit Mazumder ◽  
Mohammad Shahar Yar ◽  
Rajnish Kumar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Colon Cancer ◽  
Pancreas Cancer ◽  
New Drugs ◽  
Cancer Breast ◽  
Privileged Structures ◽  
Approved Drugs ◽  
New Research ◽  
Cancer Côlon

Abstract: New drugs introduced on the market each year have privileged structures specifically for anticancer targets, of which quinoline-based analogues also play an important role. This review lit up quinoline and its derivatives, which have great potency against various cancer cells including prostate cancer, breast cancer, colon cancer, pancreas cancer and many more. This review describes the most likely process-scale synthetic approaches of quinoline and its derivatives having specific pharmacophore, for anticancer targets along. It is also described the undergoing development and recently approved drugs in tabular form. Quinoline moiety as privileged structural pharmacophore has most effective activity against different cancer cell lines like prostate cancer, breast cancer, stomach cancer, pancreas cancer, Colon cancer, CNS cancer and renal cancer. Because of this advantage, it has the potency to grow with new research works about the anticancer as well as enhancing the value of the investigative process in the field of medicinal chemistry by introducing new effective alignments of substituents. It can be used as lead compounds for further research in the subject of anticancer drug discovery.

Absence of the CHEK2*1100delC mutation in non-BRCA1/2 families with multiple cancer types in a high-risk clinic population of Caucasian ancestry

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 11040-11040
Author(s):  
M. A. Gorin ◽  
M. D. Iniesta ◽  
J. A. Douglas ◽  
K. J. Milliron ◽  
S. D. Merajver
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
North American ◽  
North American Population ◽  
Study Cohort ◽  
Multiple Cancer ◽  
Checkpoint Kinase ◽  
Chek2 1100Delc ◽  
Increased Risk ◽  
Cancer Types

11040 Background: Checkpoint kinase 2(CHEK2) is a cell-cycle-checkpoint kinase that phosphorylates p53 and BRCA1 in response to DNA damage. The contribution of CHEK2 mutations to familial cancer has been widely studied in breast cancer. Most notably, the CHEK2*1100delC mutation has been characterized to confer a 2-fold increased risk for breast cancer in carriers. This finding comes from studies performed on Northern and Eastern European populations. Few studies, however, have been conducted in North American. In contrast to the work done in Europe, these studies suggest a lower frequency of CHEK2*1100delC mutations in breast cancer families. The aim of this study was to determine the frequency of CHEK2*1100delC in members of breast cancer families who tested negative for a deleterious mutation in BRCA1/2. Methods: DNA sequencing was used to genotype 115 individuals for CHEK2*1100delC. Families were characterized by the presence of several cases of breast and/or ovarian cancer and multiple members with other cancers in a single lineage. Given the broad variety of cancers associated with CHEK2 mutations and its function in DNA repair, we hypothesized that these families would be enriched for harboring the CHEK2*1100delC in the germline. Results: No CHEK2*1100delC mutations were detected in 115 individuals, including 39 women diagnosed with breast cancer at an early age, 7 women with bilateral cancer, 2 men with breast cancer and 6 women with ovarian cancer, all of whom were negative for mutations in BRCA1/2.The CHEK2 Breast Cancer Consortium previously reported a frequency of 2.3% for the CHEK2*1100delC mutation among breast cancer cases from families with at least 2 cases of breast cancer (or breast and ovarian cancer) in a first- or second-degree relationship. Based on that, we had approximately 92% power to detect at least one mutation among our study cohort. Conclusions: Our data are consistent with previous reports that suggest a lower frequency of CHEK2*1100delC mutations in North American hereditary breast cancer families without BRCA1/2 mutations and enriched for multiple cancer types. The low frequency of the CHEK2*1100delC in the North American population limits its clinical relevance as a cancer predisposing gene. No significant financial relationships to disclose.

scholarly journals Trends in Healthy Eating Index Scores Among Women of Varying Ethnic Backgrounds with Gynecological and Breast Cancers

2020 ◽  
Vol 4 (Supplement_2) ◽  
pp. 346-346
Author(s):  
Meghan Owens ◽  
Derek Miketinas
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Healthy Eating ◽  
Diet Quality ◽  
White Women ◽  
Healthy Eating Index ◽  
Cohen’S D ◽  
Cancer Types ◽  
Cohen's D ◽  
Hispanic White

Abstract Objectives The purpose of this study is to determine if Healthy Eating Index (HEI) scores significantly differ between women in varying ethnicity groups with self-reported gynecological cancer or breast cancer. Methods NHANES 2015–2016 data were examined to determine subjects and categorize them based on ethnicity group and self-reported cancer diagnoses. A total of 2602 women were identified and grouped by self-reported cancer diagnosis. Usual HEI scores were estimated over two days using the NCI method and adjusted for the following covariates: family income to poverty ratio, Body Mass Index, age, and smoking exposure. Ethnicity groups included were Mexican-American, Other Hispanic, Non-Hispanic White, Non-Hispanic Black, and Multiracial. Cancer diagnoses of breast, cervical, ovarian, and uterine were compared across ethnicity groups.  Independent samples t-tests and Cohen's D were calculated. Analysis was conducted using SAS version 9.4. Results Overall, diet quality was poor among the sample. Those with cervical cancer had the highest average HEI scores (48.6 + 3.0; 95% CI: 42.1 – 55.0) while those with breast cancer had the lowest average HEI scores (41.7 + 3.6; 95% CI: 34.0 – 49.3). Within those with breast cancer, non-Hispanic white women had the highest HEI scores (43.5 + 4.0; 95%CI: 34.8, 52.1) compared to other ethnicities (Cohen's D ranged between 0.28–0.42). Hispanic women with ovarian cancer had an HEI score of 26.98 points lower than white women with ovarian cancer. Overall, ethic minority groups had lower average HEI scores when compared to Non-Hispanic White women with the same type of cancer. Conclusions In some instances Non-Hipsanic white women had higher average HEI scores; however, this was not true across all cancer types. These results suggest that there are differences in diet quality scores among various cancer types, but overall diet quality is generally poor across ethnicity groups. Funding Sources None.

scholarly journals A Novel Subset of Human tumors that Simultaneously Overexpress Multiple E2F-responsive Genes Found in Breast, Ovarian, and Prostate Cancers

2014 ◽  
Vol 13s5 ◽  
pp. CIN.S14062 ◽  
Author(s):  
Stanley E. Shackney ◽  
Salim Akhter Chowdhury ◽  
Russell Schwartz
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Ovarian Cancer ◽  
Cell Cycle Progression ◽  
Multiple Organ ◽  
Serous Ovarian Cancer ◽  
Cycle Progression ◽  
Gene Expression Microarray Data ◽  
Cancer Types ◽  
Prostate Cancers

Reasoning that overexpression of multiple E2F-responsive genes might be a useful marker for RB1 dysfunction, we compiled a list of E2F-responsive genes from the literature and evaluated their expression in publicly available gene expression microarray data of patients with breast cancer, serous ovarian cancer, and prostate cancer. In breast cancer, a group of tumors was identified, each of which simultaneously overexpressed multiple E2F-responsive genes. Seventy percent of these genes were concerned with cell cycle progression, DNA repair, or mitosis. These E2F-responsive gene overexpressing (ERGO) tumors frequently exhibited additional evidence of Rb/E2F axis dysfunction, were mostly triple negative, and preferentially overexpressed multiple basal cytokeratins, suggesting that they overlapped substantially with the basal-like tumor subset. ERGO tumors were also identified in serous ovarian cancer and prostate cancer. In these cancer types, there was no evidence for a tumor subset comparable to the breast cancer basal-like subset. A core group of about 30 E2F-responsive genes were overexpressed in all three cancer types. Thus, it appears that disorders of the Rb/E2F axis can arise at multiple organ sites and produce tumors that simultaneously overexpress multiple E2F-responsive genes.

Sign in / Sign up

Export Citation Format

Share Document